C4 Therapeutics Inc (CCCC) Stock Price, Quote & News

Company Profile

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epi...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 231 0700

Website: www.c4therapeutics.com

Address:

490 Arsenal Way, Suite120, Watertown, United States

Aldinho_lbk Apr. 9 at 2:48 PM

$CCCC this is the typical case that makes the newbies to think "rigged system"... Superb news but the stock price tanks. Why is that? The price falls for two reasons: 1) the company sells shares to make money, and they sell to institutions. 2) short sellers cover using box method.

0 · Reply

zawojak Apr. 9 at 2:32 PM

$CCCC I am long here, experience tells me that this kind of pumps don't bode well for the stocks, at least short term. It could have been a favour for someone so they could exit at higher price. I know shit but it wouldn't surprise me. Many bag holders created today. This board will be lively for a while at least.

0 · Reply

MommoTrader Apr. 9 at 2:26 PM

$CCCC Just missed getting my fill at 2.88

0 · Reply

Nifty_Trader Apr. 9 at 2:21 PM

$CCCC This should see at least $5 Probably fair value is $8.X

0 · Reply

MidusS2 Apr. 9 at 2:18 PM

$CCCC Lets Short this Biatch

0 · Reply

intrader Apr. 9 at 2:17 PM

$CCCC News with Roche (one of the biggest biotech companies in the world, privately owned). C4 Therapeutics Expands Roche Partnership to Develop Degrader-Antibody Conjugates Against Cancer 08:10 AM EDT, 04/09/2026 (MT Newswires) -- C4 Therapeutics (CCCC) said Thursday it signed a new collaboration agreement with Roche to research and develop degrader-antibody conjugates to treat cancers. The company said it will receive a $20 million upfront payment for two programs against unidentified oncology targets and get an additional payment should Roche opt for a third target. C4 is also eligible to receive more than $1 billion in potential milestone payments as well as future sales royalties, according to a statement.

0 · Reply

Rybod30 Apr. 9 at 2:13 PM

$CCCC $3..

1 · Reply

bizness1957 Apr. 9 at 2:13 PM

$CCCC millions of shorts

0 · Reply

Rounderssss4 Apr. 9 at 2:12 PM

$CCCC 5 in coming

0 · Reply

bizness1957 Apr. 9 at 2:11 PM

$CCCC retest $3.96

0 · Reply

C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma

Mar 9, 2026, 4:01 PM EDT - 4 weeks ago

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Feb 26, 2026, 7:00 AM EST - 6 weeks ago

C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Feb 23, 2026, 7:10 AM EST - 6 weeks ago

C4 Therapeutics to Participate in Upcoming March Conferences

$C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma$

Feb 23, 2026, 7:00 AM EST - 6 weeks ago

C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma

Feb 4, 2026, 7:00 AM EST - 2 months ago

C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Jan 14, 2026, 7:00 AM EST - 3 months ago

C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways

Nov 25, 2025, 7:00 AM EST - 4 months ago

C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

Nov 6, 2025, 7:00 AM EST - 5 months ago

C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Oct 16, 2025, 7:08 AM EDT - 6 months ago

C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering

$C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma$

Oct 1, 2025, 7:00 AM EDT - 6 months ago

C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma

Sep 20, 2025, 11:00 AM EDT - 7 months ago

C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting

Sep 4, 2025, 7:00 AM EDT - 7 months ago

C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration

Sep 3, 2025, 7:00 AM EDT - 7 months ago

C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting

Aug 7, 2025, 7:00 AM EDT - 8 months ago

C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

May 7, 2025, 7:00 AM EDT - 1 year ago

C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Feb 27, 2025, 7:00 AM EST - 1 year ago

C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Feb 24, 2025, 7:00 AM EST - 1 year ago

C4 Therapeutics to Participate in Upcoming March Investor Conferences

Dec 8, 2024, 12:30 PM EST - 1 year ago

C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader

Nov 20, 2024, 7:00 AM EST - 1 year ago

C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors

Oct 15, 2024, 4:01 PM EDT - 1 year ago

C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.

Oct 9, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit

Sep 13, 2024, 10:00 AM EDT - 1 year ago

C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

Sep 8, 2024, 6:05 PM EDT - 1 year ago

C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024

Sep 3, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors

Aug 29, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics to Participate in Upcoming September Investor Conferences

Aug 1, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Jul 16, 2024, 4:01 PM EDT - 1 year ago

C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024

Jul 8, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day

Jun 10, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors

May 8, 2024, 7:00 AM EDT - 2 years ago

C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Apr 9, 2024, 7:00 AM EDT - 2 years ago

C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum

Apr 8, 2024, 8:00 AM EDT - 2 years ago

C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024

Mar 5, 2024, 4:30 PM EST - 2 years ago

C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024

Mar 4, 2024, 7:00 AM EST - 2 years ago

C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins

Feb 22, 2024, 7:00 AM EST - 2 years ago

C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Jan 9, 2024, 4:01 PM EST - 2 years ago

C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines

C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals

Jan 4, 2024, 4:01 PM EST - 2 years ago

C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs)

$C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma$

Nov 28, 2023, 7:00 AM EST - 2 years ago

C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma

Nov 20, 2023, 7:00 AM EST - 2 years ago

C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment

Nov 1, 2023, 7:00 AM EDT - 2 years ago

C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Oct 11, 2023, 7:00 AM EDT - 2 years ago

C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC™ Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC™ Degrader in Development for Multiple Myelom

C4 Therapeutics Announces Chief Financial Officer Succession

Sep 5, 2023, 4:01 PM EDT - 2 years ago

C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT8919, an Orally Bioavailable BiDAC™ Degrader Targeting EGFR L858R for Non-Small Cell Lung Cancer

Jun 20, 2023, 7:00 AM EDT - 3 years ago

C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer

Aldinho_lbk Apr. 9 at 2:48 PM

0 · Reply

zawojak Apr. 9 at 2:32 PM

0 · Reply

MommoTrader Apr. 9 at 2:26 PM

$CCCC Just missed getting my fill at 2.88

0 · Reply

Nifty_Trader Apr. 9 at 2:21 PM

$CCCC This should see at least $5 Probably fair value is $8.X

0 · Reply

MidusS2 Apr. 9 at 2:18 PM

$CCCC Lets Short this Biatch

0 · Reply

intrader Apr. 9 at 2:17 PM

0 · Reply

Rybod30 Apr. 9 at 2:13 PM

$CCCC $3..

1 · Reply

bizness1957 Apr. 9 at 2:13 PM

$CCCC millions of shorts

0 · Reply

Rounderssss4 Apr. 9 at 2:12 PM

$CCCC 5 in coming

0 · Reply

bizness1957 Apr. 9 at 2:11 PM

$CCCC retest $3.96

0 · Reply

Rybod30 Apr. 9 at 2:07 PM

$CCCC Trading charts resistance $2.9-$2.92, doesn’t mean much here, but🤷‍♂️😬..

0 · Reply

NSAR Apr. 9 at 2:01 PM

$CCCC why gave up premarket gains

0 · Reply

STACKD0E Apr. 9 at 2:01 PM

$CCCC

0 · Reply

bizness1957 Apr. 9 at 1:59 PM

$CCCC red to green rip

0 · Reply

Andysss Apr. 9 at 1:58 PM

$CCCC man. Now this also have become a retard board

2 · Reply

intrader Apr. 9 at 1:57 PM

$CCCC Short's should have covered 20 minutes ago at $2.67.

0 · Reply

Graphtistics Apr. 9 at 1:56 PM

$CCCC

0 · Reply

MidusS2 Apr. 9 at 1:54 PM

$CCCC Im Short , Nice green for me thanks Longs ahaha

0 · Reply

MidusS2 Apr. 9 at 1:53 PM

$CCCC The people that run this are Hopeless haha , They would not know a molecule or an atom ahaha

0 · Reply

intrader Apr. 9 at 1:50 PM

$CCCC

0 · Reply

MidusS2 Apr. 9 at 1:49 PM

$CCCC Lets take a Short on this shit stock Lets goooo !!!

0 · Reply

intrader Apr. 9 at 1:49 PM

$CCCC

0 · Reply

Market Cap	267.36M
Revenue (ttm)	35.95M
Net Income (ttm)	-104.99M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-292.04%
Debt to Equity Ratio	0.00

Volume	1,639,900
Avg Vol	2,171,292
Day's Range	N/A - N/A
Shares Out	97.58M
Stochastic %K	83%
Beta	2.85
Analysts	Strong Sell
Price Target	$11.57